News for Pacira BioSciences, Inc. (PCRX)

On May 9, 2025, Needham analyst Serge Belanger announced updates on Pacira BioSciences (PCRX). The analyst has maintained a "Buy" rating on the stock. Despite k

EXPAREL Sales: Increased to $136.5 million from $132.4 million in 2024, driven by volume growth.ZILRETTA Sales: Declined to $23.3 million from $25.8 million in

Comprehensive SWOT analysis based on the latest 10-Q filing.Financial performance highlights and strategic positioning.Deep dive into strengths, weaknesses, op

The following slide deck was published by Pacira BioSciences, Inc.

On March 31, 2025, Pacer Advisors, Inc. (Trades, Portfolio) executed a substantial reduction in its holdings of Pacira BioSciences Inc (PCRX). The firm decrease

On December 31, 2024, Pacer Advisors, Inc. (Trades, Portfolio) executed a significant reduction in its holdings of Pacira BioSciences Inc (PCRX). The firm decre

Revenue: $168.9 million, slightly below the estimated $176.03 million.Earnings Per Share (EPS): $0.10, falling short of the estimated $0.25.Net Income: $4.8 mi

Pacira Biosciences (PCRX) reported its first-quarter revenue at $168.9 million, missing the consensus estimate of $175.9 million. Despite this gap, the company

-- Conference call today at 4:30 p.m. ET -- BRISBANE, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. ( PCRX), the industry leader in its c

Pacira BioSciences (PCRX) reports Q1 Non-GAAP EPS of $0.62, beating estimates by $0.02. Revenue misses by $6.98M.

On March 31, 2025, BlackRock, Inc. (Trades, Portfolio) executed a significant transaction involving Pacira BioSciences Inc (PCRX). The firm reduced its holdings

U.S. stocks were lower, with the Dow Jones index falling around 700 points on Monday. Shares of Wolverine World Wide, Inc. WWW rose sharply during Monday's ses...

-- $300 million aggregate share repurchase authorization-- -- Reinforces confidence in 5x30 plan ”“ -- Continued focus on margin expansion and operat

Pacira BioSciences, Inc. (PCRX) has revealed that its board of directors has approved a new share buyback initiative, allowing the company to repurchase up to $

Pacira BioSciences (PCRX) announces a $300 million share repurchase program expiring in December 2026. The company's '5x30' strategy aims to treat over

We recently published a list of 10 Best Pharma Stocks to Buy for Long Term Growth. In this article, we are going to take a look at where Pacira BioSciences, Inc.

Summary Pacira BioSciences Inc (PCRX), a leader in non-opioid pain management therapies, announced on April 11, 2025, the issuance of inducement awards to 18 ne

Pacira BioSciences (PCRX) has granted inducement awards to 18 new employees under its 2014 Inducement Plan. Inducement awards include stock options for

Pacira BioSciences, trading under the ticker PCRX, has announced the issuance of inducement awards to 18 newly hired employees. This move, executed on April 2,